Skip to main content
Molecular Therapy logoLink to Molecular Therapy
. 2022 May 24;30(7):2639. doi: 10.1016/j.ymthe.2022.03.018

Retraction Notice to: Comprehensive Analysis of the Expression and Prognosis for E2Fs in Human Breast Cancer

Cheng-Cao Sun , Shu-Jun Li, Wei Hu, Jian Zhang, Qun Zhou, Cong Liu, Lin-Lin Li, Yi-Yan Songyang, Feng Zhang, Zhen-Long Chen, Guang Li, Zhuo-Yue Bi, Yong-Yi Bi, Feng-Yun Gong, Tao Bo, Zhan-Peng Yuan, Wei-Dong Hu, Bo-Tao Zhan, Qian Zhang, Qi-Qiang He ∗∗∗, De-Jia Li ∗∗
PMCID: PMC9263386  PMID: 35797981

Main text

(Molecular Therapy 27, 1153–1165, June 2019)

Molecular Therapy is retracting this article. After a reader raised concerns about the article, the Editor-in-Chief found that Figure 1 was reused without attribution to the authors' previous work (Sun et al., 2018, Aging (Albany NY) 10, 973–987, https://dx.doi.org/10.18632/aging.101441) (although the pan-cancer analysis of E2F family using Oncomine database shared the same image to summarize the transcriptional levels of E2F family in different cancer types), and images were also duplicated in Figure 4. The author maintains that Figure 1 was not reused because it was generated using Oncomine.org, and the image duplications in Figure 4 were the result of unintentional errors that do not affect the interpretation of the results. The editors maintain that these issues have raised serious concerns about the validity of the results. This reuse (and in part, misrepresentation) of data without appropriate attribution represents a severe abuse of the scientific publishing system.

Contributor Information

Cheng-Cao Sun, Email: chengcaosun@whu.edu.cn.

Qi-Qiang He, Email: heqiqiang@gmail.com.

De-Jia Li, Email: lodjlwhu@sina.com.


Articles from Molecular Therapy are provided here courtesy of The American Society of Gene & Cell Therapy

RESOURCES